My ePortfolio Register   

ESMO 2017 /
Vemurafenib for high risk melanoma patients

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 172
Rating:

Dr Karl Lewis - University of Colorado Denver, Colorado, USA

Dr Lewis presents in a press conference at the ESMO 2017 Congress in Madrid data from a randomised, double-blind, placebo-controlled study of adjuvant vemurafenib in patients with completely resected, BRAFV600 melanoma at high risk for recurrence.

Dr Lewis spoke with ecancer about the results here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence